DJIA 16,805.41 127.51 0.76%
NASDAQ 4,483.72 30.92 0.69%
S&P 500 1,964.58 13.76 0.71%
market minute promo

0.28 -0.02 (-5.35%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

HEB $0.28 -5.35%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.31
Previous Close $0.30
Daily Range $0.28 - $0.31
52-Week Range $0.19 - $0.55
Market Cap $53.8M
P/E Ratio -2.99
Dividend (Yield) $0.00 (0.0%)
Volume 1,504,820
Average Daily Volume 2,744,780
Current FY EPS $0.00

Sector

Healthcare

Industry

Drugs

Hemispherx BioPharma, Inc. (HEB) Description

A biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug entities based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Website: http://www.hemispherx.net/

News & Commentary Rss Feed

NeoStem CFO Taking on New Role at Company

Robert Dickey hired to be CFO.

Hemispherx Joins The Ebola Game

Hemispherx BioPharma: Any Pops On Ebola News Are The Time To Sell

Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC As Governmental

Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC As Governmental Counsel In Fight Against Ebola

Ebola Patient Eric Duncan Dies; Related Stocks Fall On News

Ebola Outbreak Puts the Spotlight on 10 Biotech Companies

Ebola Sector Shake Out Leaves Chimerix Inc On Top

As Ebola spreads, drug stocks surge

Ebola drug stocks surge as virus spreads to U.S.

Why You Should Stay Away From the Ebola Frenzy in Biotech Stocks

Futures Lower on Hong Kong Protests, Sluggish EU Factory Data; ADP Beats Estimates

Ebola-Stricken Doc Receives Experimental Drug, But Which One?

See More HEB News...

HEB's Top Competitors

HEB $0.28 (-5.35%)
Current stock: HEB
AMGN $147.26 (0.01%)
Current stock: AMGN
GILD $110.71 (3.29%)
Current stock: GILD
BIIB $321.67 (1.77%)
Current stock: BIIB